Full Press Release Details
NeuroSense CEO Provides
View video here: Link
Mass., July 6, 2023 -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe
neurodegenerative diseases, today provided an update from its CEO, Alon Ben-Noon, on the Company's clinical and operational developments
during the second quarter of 2023.
2b Amyotrophic Lateral Sclerosis (ALS) PARADIGM Trial Completed Patient Enrollment
Scientific Agreement with Biogen
2 Alzheimer's Disease (AD) Trial Under Preparation
Disease (PD) Biomarker Study Completed
Raise of $4.5 Million
enrollment of PARADIGM completed, we are on track to report topline results before the end of 2023 as we work on several additional value-driving
events." stated Alon Ben-Noon, CEO of NeuroSense.
Therapeutics, Ltd. is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from
debilitating neurodegenerative diseases. NeuroSense believes that these diseases, which include amyotrophic lateral sclerosis (ALS),
Alzheimer's disease and Parkinson's disease, among others, represent one of the most significant unmet medical needs of our time, with
limited effective therapeutic options available for patients to date. Due to the complexity of neurodegenerative diseases and based on
strong scientific research on a large panel of related biomarkers, NeuroSense's strategy is to develop combined therapies targeting multiple
pathways associated with these diseases.
press release contains "forward-looking statements" that are subject to substantial risks and uncertainties. All statements,
other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained
in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate,"
"could," "estimate," "expect," "intend," "seek," "may," "might,"
"plan," "potential," "predict," "project," "target," "aim," "should,"
"will" "would," or the negative of these words or other similar expressions, although not all forward-looking statements
contain these words. Forward-looking statements are based on NeuroSense Therapeutics' current expectations and are subject to inherent
uncertainties, risks and assumptions that are difficult to predict and include statements regarding the timing of preclinical and clinical
data for PrimeC and the timing of enrollment for clinical trials. Further, certain forward-looking statements are based on assumptions
as to future events that may not prove to be accurate and actual results could differ materially and adversely from those anticipated
or implied in the forward looking statements due to a number of risks and uncertainties. Such risks and uncertainties include a delay
in the reporting of top-line results from our ALS Phase 2b clinical trial, a delay in commencement of our Phase 2 study in Alzheimer's
and a delay in other clinical and regulatory milestones. More information about the risks and uncertainties affecting the Company is contained
under the heading "Risk Factors" in the Annual Report on Form 20-F filed with the Securities and Exchange Commission on March
22, 2023. You should not rely on these statements as representing our views in the future. Forward-looking statements contained in this
announcement are made as of this date, and NeuroSense Therapeutics Ltd. undertakes no duty to update such information except as required
under applicable law.
information: Email: info@neurosense-tx.com, Tel: +972 (0)9 799 6183